Enfortumab Vedotin and Pembrolizumab - A New Perspective on Urothelial Cancer
Overview
Authors
Affiliations
Shi X, Tang K, Zhang Q, Han Q, Quan L, Li Y Front Pharmacol. 2025; 16:1556245.
PMID: 40061961 PMC: 11885230. DOI: 10.3389/fphar.2025.1556245.
Time's up: the urgency to investigate time toxicity in patients with genitourinary malignancies.
Sentana-Lledo D, Morgans A Ther Adv Med Oncol. 2024; 16:17588359241305088.
PMID: 39664299 PMC: 11632889. DOI: 10.1177/17588359241305088.
Zhang T, Tan A, Shah A, Iyer G, Morris V, Michaud S Oncologist. 2024; 29(12):1003-1013.
PMID: 39167703 PMC: 11630754. DOI: 10.1093/oncolo/oyae215.
Gasperoni L, Del Bono L, Ossato A, Giunta E, Messori A, Damuzzo V Cancers (Basel). 2024; 16(13).
PMID: 39001462 PMC: 11240305. DOI: 10.3390/cancers16132400.